394 related articles for article (PubMed ID: 34341011)
1. EUS-based Pancreatic Cancer Surveillance in
Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
[TBL] [Abstract][Full Text] [Related]
2. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
5. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
[TBL] [Abstract][Full Text] [Related]
6. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.
Abe T; Blackford AL; Tamura K; Ford M; McCormick P; Chuidian M; Almario JA; Borges M; Lennon AM; Shin EJ; Klein AP; Hruban RH; Canto MI; Goggins M
J Clin Oncol; 2019 May; 37(13):1070-1080. PubMed ID: 30883245
[TBL] [Abstract][Full Text] [Related]
7. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study.
Furniss CS; Yurgelun MB; Ukaegbu C; Constantinou PE; Lafferty CC; Talcove-Berko ER; Schwartz AN; Stopfer JE; Underhill-Blazey M; Kenner B; Nelson SH; Okumura S; Law S; Zhou AY; Coffin TB; Rodriguez NJ; Uno H; Ocean AJ; McAllister F; Lowy AM; Lippman SM; Klein AP; Madlensky L; Petersen GM; Garber JE; Goggins MG; Maitra A; Syngal S
Cancer Prev Res (Phila); 2021 Nov; 14(11):1021-1032. PubMed ID: 34625409
[TBL] [Abstract][Full Text] [Related]
8. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
[TBL] [Abstract][Full Text] [Related]
9. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants.
Laish I; Schechter M; Dancour A; Lieberman S; Levi Z; Goldberg Y; Kedar I; Hasnis E; Half E; Levi GR; Katz L; Vainer ED; Genzel D; Aharoni M; Chen-Shtoyerman R; Abu-Freha N; Raitses-Gurevich M; Golan T; Bernstein-Molho R; Ben Yehoyada M; Gluck N; Rosner G
Cancer; 2024 Jan; 130(2):256-266. PubMed ID: 37861363
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
[TBL] [Abstract][Full Text] [Related]
11. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
12. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing.
Jiang H; Huang F; Chen X; Zhang L; Shen M; Pan B; Wang B; Guo W
Mol Genet Genomic Med; 2023 Jul; 11(7):e2170. PubMed ID: 36978154
[TBL] [Abstract][Full Text] [Related]
13. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
Kimura H; Mizuno K; Shiota M; Narita S; Terada N; Fujimoto N; Ogura K; Hatano S; Iwasaki Y; Hakozaki N; Ishitoya S; Sumiyoshi T; Goto T; Kobayashi T; Nakagawa H; Kamoto T; Eto M; Habuchi T; Ogawa O; Momozawa Y; Akamatsu S
Br J Cancer; 2022 Nov; 127(9):1680-1690. PubMed ID: 35986085
[TBL] [Abstract][Full Text] [Related]
15. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
16. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
[TBL] [Abstract][Full Text] [Related]
17. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH
Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780
[TBL] [Abstract][Full Text] [Related]
19. Germline testing of
Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
[TBL] [Abstract][Full Text] [Related]
20. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
Roch AM; Schneider J; Carr RA; Lancaster WP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM; Ceppa EP
J Surg Oncol; 2019 May; 119(6):777-783. PubMed ID: 30636051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
